Quantcast

Latest Cancer treatments Stories

2014-03-19 08:29:07

Data Presented at 9th European Breast Cancer (EBCC-9) Symposium Highlights Comprehensive Body of Clinical Evidence for Oncotype DX REDWOOD CITY, Calif., March 19, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9(th) European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that...

2014-03-18 08:33:40

CAMBRIDGE, Mass., March 18, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2 trial designed to (1) identify the recommended Phase 2 dose of CRLX101 in combination with Xeloda(®) (capecitabine) and radiation (chemoradiotherapy) and (2) detect signals, if any, of increased efficacy over standard neoadjuvant chemoradiotherapy for rectal cancer. The trial is...

2014-03-17 20:22:32

TOORAK, Australia, March 17, 2014 /PRNewswire/ -- Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept trial of ATL1102, the Company's second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells (CD34+) into the blood when dosed alone and in combination with an existing...

2014-03-17 12:27:23

Union Creates Global Leader In Targeted Oncolytic Immunotherapy BUSAN, South Korea and SAN FRANCISCO, March 17, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today that it had completed the acquisition of San Francisco-based Jennerex, Inc. Privately-held Jennerex is a clinical-stage, biotherapeutics company recognized as a global leader in the development of...

2014-03-17 08:29:24

NCI study to investigate whether third generation CAR T Cells can be eliminated if they become harmful HOUSTON, March 17, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that the first clinical study is underway of a Chimeric Antigen Receptor (CAR) T Cell therapy that incorporates a safety switch to enable rapid elimination of the administered T cells if they threaten the life or health of the patient. Researchers from the National Cancer Institute (NCI) have...

2014-03-17 08:29:07

HOUSTON, March 17, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers. "Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to push ahead for more effective...

2014-03-16 23:01:40

Researchers say resveratrol slows cancer growth without the toxicity and irritation of chemotherapy. Raleigh, NC (PRWEB) March 16, 2014 A new report published on PLoS One and detailed by Cancer Monthly suggests that a natural phenol credited with giving red wine its anti-aging properties may also help fight bladder cancer. Bladder cancer accounts for about 2.6% of cancer deaths in the US and is more prevalent in diabetics than in the general public. Certain drugs, including the drug...

2014-03-12 12:28:28

ORLANDO, Fla., March 12, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC: TNIB), a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy through the acquisition and licensing of late development stage compounds, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for IRT-101 (MENK) for inducing sustained immune response of T-Cells. The...

2014-03-11 08:31:55

Global breast cancer survey demonstrates physicians generally prefer standard of care chemotherapy as compared to newly approved targeted therapies NEW YORK, March 11, 2014 /PRNewswire/ -- OBiS releases preliminary results from its 2014 global physician breast cancer survey. The survey included treatment data and insights from over 50 countries and 500 treating physicians. Data demonstrated that despite a number of newly approved targeted therapies, most physicians treated their...

2014-03-07 08:25:29

SYDNEY, March 7, 2014 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTC:VRACY) will present at two prominent U.S. healthcare investment conferences next week. CEO Dr Malcolm McColl will present on March 10 at the 26th Annual ROTH Investment Conference in Dana Point, California. The ROTH conference is one of the largest of its kind in the U.S. with approximately 3,000 attendees including 1,000 from the global investment community. On March 12 Dr. McColl will present at the Bernstein Emerging...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'